The National Cancer Institute (NCI) seeks licensing partners for a novel modified insect cell line, Sf9-ET, that can quickly and efficiently determine baculovirus titers during the expression of recombinant proteins from a baculovirus-based protein expression system.
The National Eye Institute (NEI) seeks research co-development or licensees for making research- or clinical-grade preservation solutions for cold-sensitive organ transplantation or protection of brain injury or trauma during surgery.
Researchers at the National Cancer Institute (NCI) have developed a bioluminescent MB49-luciferase bladder cancer cell line that can be used in preclinical studies to evaluate anti-cancer agents in bladder cancer. NCI seeks parties to non-exclusively license this research material.
Scientists at the National Cancer Institute have developed a cell line designated A549 that was derived from explanted cultures of human lung cancer tissue. The A549 cell line has been tested under the guidance of the United States Food and Drug Administration (FDA) so, under current Good Manufacturing Practices (GMP), these cells may be suitable for use in manufacturing constructs for use in clinical trials. The National Cancer Institute seeks parties to non-exclusively license this research material.
NIH scientists created and characterized an excellent mouse model for TNBC that shares important molecular characteristics of human TNBC making it highly useful for preclinical testing of drugs and novel therapies. This model may provide a valuable means of identifying new drugs and therapies that could be translated to human clinical trials.The NCI seeks parties interested in licensing this mouse model of prostate and triple-negative breast cancers to study cancer biology and for preclinical testing.
The Biorepositories and Biospecimen Research Branch (BBRB) at the National Cancer Institute (NCI) has sponsored various initiatives for conducting biospecimen research. Through these initiatives, NCI seeks to advance biospecimen science and improve research reproducibility by investigating how different biospecimen collection, handling and processing procedures affect biospecimen molecular profiles. BBRB is seeking collaborators to extend these studies.
The National Cancer Institute (NCI) seeks non-exclusive licensees for an ovarian cancer cell line, A2780, and its cisplatin- and/or adriamycin-resistant derivatives, A2780CIS and A2780ADR. These cell lines are excellent research tools to study ovarian cancer with a focus on drug resistance.
Adoptive cell therapy (ACT) uses cancer reactive T-cells to effectively treat cancer patients. Producing many persistent T-cells is critical for successful treatments. Researchers at the National Cancer Institute (NCI) have developed a method of producing larger populations of minimally-differentiated T-cells. NCI seeks licensing and/or co-development research collaborations to further develop, evaluate, and/or commercialize this novel method of producing effective T-cell populations using p38 mitogen-activated protein kinase (MAPK) inhibitors.
The Hippo signaling pathway is one of the most frequently altered pathways in human cancer. Researchers at the National Cancer Institute (NCI) have developed a genetically encoded peptide inhibitor of the Hippo signaling pathway members YAP1/TAZ-TEAD, to dissect and study the specific TEAD-downstream regulatory gene expression networks of cell proliferation, tissue homeostasis, and stem cell functions in different cell types and pathologies. The DNA construct encoding this inhibitor may be delivered to cells using lentivirus, adenovirus, or adeno-associated virus, and is a valuable research tool. NCI seeks licensees for this peptide inhibitor and the encoding DNA construct.
Researchers at the National Cancer Institute, Laboratory of Cancer Biology and Genetics believe that a better understanding of GATA-3 function and dysregulated during the onset and progression of breast cancer will lead to new strategies in diagnosing and treating the disease.
Researchers at the NCI developed a non-invasive method for distinguishing benign from malignant adrenocortical tumors using urine samples. The NCI seeks parties to co-develop a non-invasive, diagnostic method of distinguishing between benign and malignant adrenocortical tumors through the analysis of metabolites using urine samples.
The National Eye Institute (NEI) seeks research collaborations and/or licensees for the use of induced pluripotent stem cells (IPS cells) derived from patients with CEP290 associated ciliopathies. IPS cells were derived from patients with Leber-congenital amaurosis and their unaffected relatives.
Scientists at the National Eye Institute (NEI) have developed an embryo culture chamber, which can be used to culture and image embryos. The chamber allows for the continuous imaging of the embryo for the culture period. NEI seeks research collaborations and/or licensees for the development of this culture and imaging chamber for murine embryos.
Recombinant human tissue inhibitors of metalloproteinases (rhTIMP-2) have been shown to suppress tumor growth and tumor-associated angiogenesis. NCI Radiation Oncology Branch (ROB) researchers have developed a unique HEK-293F cell line which stably expresses rhTIMP-2, increasing the production of TIMP-2 to quantities sufficient to be used for testing and development as a therapeutic for various cancers, ischemic diseases (myocardial infarct and cerebrovascular infarct), and neurodegenerative diseases.